Regeneus Valuation

Is RGS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RGS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RGS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RGS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RGS?

Key metric: As RGS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RGS. This is calculated by dividing RGS's market cap by their current revenue.
What is RGS's PS Ratio?
PS Ratio	4x
Sales	AU$988.43k
Market Cap	AU$1.53m

RGS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.5x
Enterprise Value/EBITDA	-2.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RGS's PS Ratio compare to its peers?

The above table shows the PS ratio for RGS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	15.7x
BP8 BPH Global	14.4x	n/a	AU$1.6m
HXL Hexima	35.2x	n/a	AU$2.2m
NC6 Nanollose	9.6x	n/a	AU$2.9m
VBS Vectus Biosystems	3.6x	n/a	AU$4.2m
RGS Regeneus	4x	n/a	AU$1.5m

Price-To-Sales vs Peers: RGS is good value based on its Price-To-Sales Ratio (4x) compared to the peer average (5.9x).

Price to Sales Ratio vs Industry

How does RGS's PS Ratio compare vs other companies in the AU Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
ARX Aroa Biosurgery	3.5x	22.8%	US$154.64m
IMC Immuron	3.6x	59.7%	US$11.47m
BNO Bionomics	2.4x	-5.3%	US$9.52m
CHM Chimeric Therapeutics	1.1x	n/a	US$5.29m

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: RGS is good value based on its Price-To-Sales Ratio (4x) compared to the Australian Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is RGS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RGS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RGS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$37.9m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.13

6.1%

AVITA Medical

US$338.4m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.91

-0.3%

18.5%

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.63

1.6%

-18.5%